LSA
TEVA icon

L & S Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

L & S Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-82,183
Closed -$5.39M – 101
2015
Q4 		$5.39M Buy
82,183
+35,525
+76% +$2.2M 1.35% 27
2015
Q3 		$2.63M Buy
+46,658
New +$3.03M 0.77% 56

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

L & S Advisors's TEVA Position: Q1 2016 in Review

L & S Advisors sold out of Teva Pharmaceuticals (TEVA) in Q1 2016, closing a stake of 82,183 shares — an estimated $5.39M sold.

L & S Advisors first reported a position in TEVA in Q3 2015 and held it in 2 quarters. The position peaked at $5.39M in Q4 2015. 836 funds tracked by Wall St. Rank hold TEVA as of Q1 2016.

  • L & S Advisors reported no remaining Teva Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • L & S Advisors sold 82,183 Teva Pharmaceuticals shares in Q1 2016, an estimated $5.39M.
  • L & S Advisors first reported a position in Teva Pharmaceuticals in Q3 2015 and held it in 2 quarters.
  • L & S Advisors's Teva Pharmaceuticals position peaked at $5.39M in Q4 2015.
  • 836 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2016.

Based on L & S Advisors's 13F filing for Q1 2016, filed 13 May 2016.